Pfizer Inc. (NYSE:PFE) is set to release its Q415 earnings data before the market opens on Tuesday, February 2nd. Analysts expect Pfizer to post earnings of $0.52 per share and revenue of $13.54 billion for the quarter.

Other hedge funds recently made changes to their positions in the company. Simplex Trading increased its stake in shares of Pfizer by 94.3% in the fourth quarter. Simplex Trading now owns 4,986 shares of the biopharmaceutical company’s stock valued at $903,000 after buying an additional 2,420 shares during the period. Vicus Capital increased its stake in shares of Pfizer by 17.6% in the fourth quarter. Vicus Capital now owns 8,547 shares of the biopharmaceutical company’s stock valued at $276,000 after buying an additional 1,282 shares during the period. Texan Capital Management increased its stake in shares of Pfizer by 8.8% in the fourth quarter. Texan Capital Management now owns 12,905 shares of the biopharmaceutical company’s stock valued at $417,000 after buying an additional 1,040 shares during the period. Signaturefd LLC increased its stake in shares of Pfizer by 21.1% in the fourth quarter. Signaturefd LLC now owns 14,470 shares of the biopharmaceutical company’s stock valued at $467,000 after buying an additional 2,521 shares during the period. Finally, Watch Point Trust Company bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $704,000.

Shares of Pfizer Inc. (NYSE:PFE) opened at 30.49 on Monday. The company’s 50-day moving average is $31.56 and its 200 day moving average is $33.11. Pfizer Inc. has a 1-year low of $28.47 and a 1-year high of $36.46. The firm has a market capitalization of $188.21 billion and a price-to-earnings ratio of 22.89.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 2nd. Stockholders of record on Friday, February 5th will be paid a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.94%. The ex-dividend date is Wednesday, February 3rd. This is a boost from Pfizer’s previous quarterly dividend of $0.24.

PFE has been the subject of a number of recent research reports. Jefferies Group increased their price objective on shares of Pfizer to $48.00 and gave the company a “buy” rating in a research note on Monday, December 7th. Vetr upgraded shares of Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.47 target price for the company in a research report on Tuesday, October 6th. Cowen and Company upgraded shares of Pfizer from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $25.00 to $43.00 in a research report on Tuesday, October 20th. Zacks Investment Research cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Monday, January 4th. Finally, Atlantic Securities began coverage on shares of Pfizer in a research report on Friday, December 18th. They set an “overweight” rating and a $39.00 target price for the company. Five analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $39.78.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (NYSE:PFE), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.

12 Month Chart for NYSE:PFE

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.